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Over the past 30 years, the cumulative results of clinical,
experimental, and theoretical studies have validated the
concept that slow conduction, related at least in part to
changes in intercellular coupling via gap junctions, plays an
important role in the pathogenesis of ventricular tachycardia
(VT) after myocardial infarction. Long before the major
cardiac gap junction protein, connexin43 (Cx43), was first
cloned by Beyer et al. (1) in 1987, the basic relationship
between electrical coupling and the speed of impulse prop-
agation had been recognized through the pioneering work
of Barr, Dewey, Lieberman, Kootsey, Johnson, Spach, and
many others (2–5).
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As early as 1961 (6) and certainly by the early 1980s, it had
been shown that “fractionated electrograms” and “continu-
ous electrical activity” could be identified in myocardial
regions bordering healed infarcts, and they became manifest
as fibrous tissue accumulated during infarct healing (7–10).
Although it was also understood that slow conduction could
be related to factors independent of those responsible for
producing fractionated electrograms, the presence of frac-
tionated electrograms in the setting of chronic ischemic
heart disease was consistently linked to slowing of impulse
propagation (7–10). At the same time, it was becoming
apparent that fractionated electrograms persisted in healed
infarct border zones once acute post-infarct derangements
in resting membrane potential and active ionic currents had
normalized (7–10). Taken together, these observations led
to the conclusion that fractionated electrograms and slow
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result of diminished intercellular electrical coupling, associ-
ated with separation of fibers by peri-infarct scar tissue. This
concept, articulated most lucidly by Josephson and Wit in
the early 1980s (9,10) and later by de Bakker et al. (11), had
its origins in seminal experimental work by Spach (4,5),
Waldo and Kaiser (12), Boineau and Cox (13), El-Sherif
et al. (14), Spear (15,16), Spear et al. (15,16), and others. It
has since been strengthened by morphometric and immu-
nohistochemical studies documenting gap junction remod-
eling in viable cardiac myocytes bordering healed infarcts
(17–19) and ever more powerful in vitro and computational
studies defining specific structural and electrophysiological
determinants of slow conduction under various conditions
and elucidating their pathophysiological consequences (20–
22). Although it is true that these studies have differed in
terms of the animal species, experimental protocols, and
theoretical models used and have involved different types of
measurements at different intervals after infarction, they
have all converged on the idea that gap junction remodeling
can reduce intercellular coupling and thereby slow conduc-
tion in ways that contribute importantly to the pathogenesis
of re-entrant VT after myocardial infarction. Recognition of
this concept has also raised the obvious possibility that
preservation or enhancement of intercellular coupling in the
infarct border zone might decrease the risk for re-entrant
VT, an idea originally proposed in studies pre-dating the
modern era of molecular biology and genetic engineering.
Of course, ventricular arrhythmias are complex phenom-
ena, often thought of as arising from multiple input deter-
minants and initiated by stochastic events. It has been
challenging, therefore, to apply conventional reductionist
approaches to identify the specific contributions of any
individual factor, and without such knowledge, the devel-
opment of rational mechanism-based therapies becomes
even more challenging. The advent of genetic engineering
has made possible gain-of-function or loss-of-function
studies that have certainly advanced our understanding of
the key determinants of arrhythmogenesis, but most of
these studies have been performed in vitro or in mice, which
have unavoidable limitations as models of arrhythmias in
human heart disease. Precise genetic interventions in a large
animal model would be of great potential value, therefore, in
elucidating the role of specific molecules in VT after
myocardial infarction.
Now, in this issue of the Journal, Greener et al. (23)
report the use of a state-of-the-art targeted gene transfer
approach in a large animal model to provide an important
new demonstration of the critical role of Cx43 expression
and, by inference, cell-cell coupling, in the development of
fractionated electrograms, slow conduction, and VT induc-
ibility in the healed infarct border zone. Greener et al. (23)
subjected Yorkshire pigs to transient left anterior descend-
ing coronary artery occlusion to produce infarction and then
monitored arrhythmia inducibility as the infarcts healed.
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monomorphic VT 4 weeks after infarction, by which time
infarct healing was largely completed, and the area previ-
ously occupied by necrotic myocardium was composed of
maturing scar tissue. Some animals then underwent adeno-
viral gene transfer in which the Cx43 gene was targeted to
the infarct border-zone region by selective delivery via the
infarct artery. Others received a control virus containing
beta-galactosidase to independently identify the region of
gene transfer but without any expected effect on Cx43
expression. A third group received no virus. A week later,
animals receiving the Cx43 gene showed less electrogram
fractionation and faster conduction velocity in the infarct
border zone. Only 4 of 10 receiving the Cx43 construct were
inducible for VT, whereas all of the controls remained
inducible after gene transfer. The border-zone region con-
tained a 2-fold greater amount of Cx43 but with similar
proportions of phosphorylated Cx43 and Cx43 localized to
cell-cell junctions (both of which relate in complex ways to
channel function). The diminished electrical fractionation
suggests that enhanced expression of Cx43 partially reversed
microscopic heterogeneity in excitation, producing a more
uniform propagation pattern that, at the scale of mapping
used in this study, would be manifest as an increase in
velocity. Greener et al. (23) conclude that increased expres-
sion of Cx43 in healed infarct border zones is sufficient to
reduce arrhythmia susceptibility, and they suggest further
that targeted Cx43 gene transfer might be a viable future
therapy in patients with post-infarction VT.
A skeptic might ask where the significant advance in this
work lies. Although the investigators have pioneered the
development of gene transfer methods, they used an existing
approach in the present study (24). They have also previ-
ously demonstrated that connexin gene transfer improves
conduction velocity and prevents atrial fibrillation in a
model involving Yorkshire pigs (25). And, as observed in
this editorial comment, we have had more than 3 decades of
research linking reduced cell-cell coupling and connexin
expression to the development of fractionated electrograms,
conduction slowing, and VT in the post-infarction setting.
Taken together, this might lead one to suggest that the
conceptual advance in the present study is modest.
Nevertheless, the study by Greener et al. (23) is signifi-
cant for several reasons. First, it is probably the most direct
proof to date that augmenting Cx43 expression in the
healed infarct border zone is sufficient to reduce arrhyth-
mogenesis in a large animal model that is far more pertinent
to human disease than similar models in mice. Second, it
establishes potential clinical efficacy and provides a compel-
ling rationale for future therapeutics advances. As noted by
the investigators, questions remain about the durability of
the effect and the possibility of creating new slow conduc-
tion pathways which could have a deleterious effect. Such
questions can be answered only by additional work and
depend on further advances in gene transfer technology, but
we now have a model and a method with which to moveforward. Third, the approach taken by Greener et al. (23)
appears to avoid potential risks and unintended conse-
quences inherent in other antiarrhythmic strategies, such as
manipulating repolarization or using pharmacological
agents to maintain opening of gap junction channels. The
former strategy can increase the risk for arrhythmogenicity,
whereas the latter is designed to counteract the presumably
adaptive responses of gap junction channels in response to
injury or stress (26). Potential clinical applications of so-
called antiarrhythmic peptides or other compounds de-
signed to keep gap junction channels open run the risk of
increasing infarct size by allowing unimpeded junctional
spread of injurious metabolites of ischemia. In contrast,
Greener et al. (23) provide at least some evidence that
although their approach increases Cx43 expression, the
resultant channels presumably respond normally to environ-
mental cues and would close appropriately in response to
acute ischemia. Whether this might still lead to adverse
outcomes remains to be seen, but this approach would
appear to be more physiological and therefore potentially
safer than the alternatives.
Finally, the impressive technical success of this work and
the resultant triumph of the reductionist approach should
not obscure our growing appreciation of the remarkably
complex interrelatedness of the individual components in
living systems. The importance of a systems-based ap-
proaches in cardiovascular therapeutics, so eloquently artic-
ulated by Loscalzo (27), reminds us that “disease and
pharmacology, like life itself, are much more complicated
than reductionist simplicity could ever allow, and failing to
acknowledge this complexity is an increasingly perilous
proposition.” No one would suggest that augmenting Cx43
expression in the healed infarct border zone is the ultimate
solution to the problem of post–myocardial infarction ar-
rhythmias. Rather, we must continue to strive toward a deeper
understanding of arrhythmia mechanisms, although in the
end, phenotypic screening may be the most efficient path to
identification of truly effective antiarrhythmic therapies.
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